TY - JOUR
T1 - Breast cancer risk, worry, and anxiety
T2 - Effect on patient perceptions of false-positive screening results
AU - Lee, Janie M.
AU - Lowry, Kathryn P.
AU - Cott Chubiz, Jessica E.
AU - Swan, J. Shannon
AU - Motazedi, Tina
AU - Halpern, Elkan F.
AU - Tosteson, Anna N.A.
AU - Gazelle, G. Scott
AU - Donelan, Karen
N1 - Funding Information:
This work was supported by National Institutes of Health ( NIH ) grant NIH K07-CA128816 (JML), American Cancer Society ( ACS ) grant RSGHP-07-266-01-CPHS (KD and JSS), a National Cancer Institute grant P01 CA154292 (ANAT) and by the Eleanor and Miles Shore Scholars in Medicine Fellowship (JML, TM).
Funding Information:
JML and KPL receive research support from GE Healthcare. GSG was previously a consultant for GE Healthcare until 2018.This work was supported by National Institutes of Health (NIH) grant NIH K07-CA128816 (JML), American Cancer Society (ACS) grant RSGHP-07-266-01-CPHS (KD and JSS), a National Cancer Institute grant P01 CA154292 (ANAT) and by the Eleanor and Miles Shore Scholars in Medicine Fellowship (JML, TM).
Publisher Copyright:
© 2020 The Authors
PY - 2020/4
Y1 - 2020/4
N2 - Objective: The impact of mammography screening recall on quality-of-life (QOL) has been studied in women at average risk for breast cancer, but it is unknown whether these effects differ by breast cancer risk level. We used a vignette-based survey to evaluate how women across the spectrum of breast cancer risk perceive the experience of screening recall. Methods: Women participating in mammography or breast MRI screening were recruited to complete a vignette-based survey. Using a numerical rating scale (0–100), women rated QOL for hypothetical scenarios of screening recall, both before and after benign results were known. Lifetime breast cancer risk was calculated using Gail and BRCAPRO risk models. Risk perception, trait anxiety, and breast cancer worry were assessed using validated instruments. Results: The final study cohort included 162 women at low (n = 43, 26%), intermediate (n = 66, 41%), and high-risk (n = 53, 33%). Actual breast cancer risk was not a predictor of QOL for any of the presented scenarios. Across all risk levels, QOL ratings were significantly lower for the period during diagnostic uncertainty compared to after benign results were known (p < 0.05). In multivariable regression analyses, breast cancer worry was a significant predictor of decreased QoL for all screening scenarios while awaiting results, including scenarios with non-invasive imaging alone or with biopsy. High trait anxiety and family history predicted lower QOL scores after receipt of benign test results (p < 0.05). Conclusions: Women with high trait anxiety and family history may particularly benefit from discussions about the risk of recall when choosing a screening regimen.
AB - Objective: The impact of mammography screening recall on quality-of-life (QOL) has been studied in women at average risk for breast cancer, but it is unknown whether these effects differ by breast cancer risk level. We used a vignette-based survey to evaluate how women across the spectrum of breast cancer risk perceive the experience of screening recall. Methods: Women participating in mammography or breast MRI screening were recruited to complete a vignette-based survey. Using a numerical rating scale (0–100), women rated QOL for hypothetical scenarios of screening recall, both before and after benign results were known. Lifetime breast cancer risk was calculated using Gail and BRCAPRO risk models. Risk perception, trait anxiety, and breast cancer worry were assessed using validated instruments. Results: The final study cohort included 162 women at low (n = 43, 26%), intermediate (n = 66, 41%), and high-risk (n = 53, 33%). Actual breast cancer risk was not a predictor of QOL for any of the presented scenarios. Across all risk levels, QOL ratings were significantly lower for the period during diagnostic uncertainty compared to after benign results were known (p < 0.05). In multivariable regression analyses, breast cancer worry was a significant predictor of decreased QoL for all screening scenarios while awaiting results, including scenarios with non-invasive imaging alone or with biopsy. High trait anxiety and family history predicted lower QOL scores after receipt of benign test results (p < 0.05). Conclusions: Women with high trait anxiety and family history may particularly benefit from discussions about the risk of recall when choosing a screening regimen.
UR - http://www.scopus.com/inward/record.url?scp=85080065377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080065377&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2020.02.004
DO - 10.1016/j.breast.2020.02.004
M3 - Article
C2 - 32135458
AN - SCOPUS:85080065377
SN - 0960-9776
VL - 50
SP - 104
EP - 112
JO - Breast
JF - Breast
ER -